CLINICAL TRIALS PROFILE FOR SPIRIVA
✉ Email this page to a colleague
All Clinical Trials for SPIRIVA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00144196 ↗ | 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD) | Completed | Boehringer Ingelheim | Phase 4 | 2004-03-01 | To show that treatment with tiotropium inhalation capsules (18 μg q.d.) via HandiHaler® improves lung function in patients with mild COPD according to Swedish guidelines. |
| NCT00144326 ↗ | A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (C | Completed | Boehringer Ingelheim | Phase 3 | 2003-07-01 | The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of daily physical activity observed in COPD patients, measured using an accelerometer. |
| NCT00144339 ↗ | Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients | Completed | Boehringer Ingelheim | Phase 3 | 2002-12-01 | The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD. |
| NCT00157235 ↗ | Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients | Completed | Boehringer Ingelheim | Phase 3 | 2002-09-01 | The objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation. |
| NCT00239408 ↗ | Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). | Completed | Boehringer Ingelheim | Phase 4 | 2002-12-01 | Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status. |
| NCT00239421 ↗ | A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 4 | 2003-11-01 | To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol plus fluticasone in COPD patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPIRIVA
Condition Name
Clinical Trial Locations for SPIRIVA
Trials by Country
Clinical Trial Progress for SPIRIVA
Clinical Trial Phase
Clinical Trial Sponsors for SPIRIVA
Sponsor Name
